Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IOVA 
Iovance Biotherapeutics Inc (IOVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: IOVA (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $10.7
1 Year Target Price $10.7
| 5 | Strong Buy |
| 3 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 53.04% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 581.05M USD | Price to earnings Ratio - | 1Y Target Price 10.7 |
Price to earnings Ratio - | 1Y Target Price 10.7 | ||
Volume (30-day avg) 12 | Beta 0.86 | 52 Weeks Range 1.64 - 12.51 | Updated Date 07/2/2025 |
52 Weeks Range 1.64 - 12.51 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -176.49% | Operating Margin (TTM) -245.77% |
Management Effectiveness
Return on Assets (TTM) -27.14% | Return on Equity (TTM) -51.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 271714489 | Price to Sales(TTM) 2.73 |
Enterprise Value 271714489 | Price to Sales(TTM) 2.73 | ||
Enterprise Value to Revenue 1.28 | Enterprise Value to EBITDA -8.68 | Shares Outstanding 333934016 | Shares Floating 280347936 |
Shares Outstanding 333934016 | Shares Floating 280347936 | ||
Percent Insiders 0.35 | Percent Institutions 81.25 |
Upturn AI SWOT
Iovance Biotherapeutics Inc
Company Overview
History and Background
Iovance Biotherapeutics, Inc. (IOVA) was founded in 2007. It focuses on developing and commercializing cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL) technology. The company has progressed from preclinical research to late-stage clinical trials, achieving significant milestones in cell therapy for solid tumors.
Core Business Areas
- Tumor-Infiltrating Lymphocyte (TIL) Therapy: Iovance's core business is developing and commercializing TIL-based immunotherapies. This involves isolating, expanding, and re-infusing a patient's own immune cells to target and destroy cancer cells.
Leadership and Structure
Iovance Biotherapeutics Inc's leadership team includes Frederick Vogt (Interim CEO), Igor Bilinsky (Chief Scientific Officer), and Wayne Rothbaum (Chairman of the Board). The company has a functional organizational structure with departments focused on research, clinical development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Lifileucel (AMTAGVI): Lifileucel is a TIL therapy approved for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor. Its approval date was Feburary 16, 2024. Competitors include traditional melanoma treatments like surgery, radiation, chemotherapy, targeted therapies, and other immunotherapies like PD-1 inhibitors (Keytruda, Opdivo) and CTLA-4 inhibitors (Yervoy). Currently, it holds the first-to-market position for approved TIL therapy in melanoma.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing rapid growth due to its effectiveness in treating various cancers. Cell therapies like TIL are becoming increasingly important, offering potential for durable responses in patients with advanced solid tumors.
Positioning
Iovance is a leader in the TIL therapy field. The companyu2019s first approval in melanoma, sets it up to expand into other solid tumors. Iovance holds a competitive advantage with its established manufacturing processes.
Total Addressable Market (TAM)
The total addressable market for cell-based cancer therapies is estimated in the tens of billions of dollars annually, with projections for continued growth. Iovance is positioned to capture a significant share of this market by expanding the use of its TIL platform to treat various solid tumors and potentially earlier lines of therapy.
Upturn SWOT Analysis
Strengths
- First approved TIL therapy
- Proprietary TIL technology platform
- Experienced management team
- Advanced manufacturing capabilities
- Strong clinical data for Lifileucel
Weaknesses
- High cost of TIL therapy
- Complex manufacturing process
- Limited commercial experience
- Dependence on single product (Lifileucel)
- Reliance on success in clinical trials for other indications
Opportunities
- Expand Lifileucel to other solid tumors (e.g., non-small cell lung cancer, cervical cancer)
- Develop next-generation TIL therapies
- Partner with other companies to expand market reach
- Improve manufacturing efficiency to reduce costs
- Secure favorable reimbursement policies
Threats
- Competition from other immunotherapy companies
- Regulatory hurdles and delays
- Manufacturing challenges and supply chain disruptions
- Unfavorable clinical trial results
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
Competitive Landscape
Iovance has a competitive advantage with their first-to-market status with a TIL product for melanoma, but faces strong competition from established players with broad immunotherapy portfolios.
Growth Trajectory and Initiatives
Historical Growth: Limited revenue history as it is a pre-commercial company.
Future Projections: Future growth depends on successful launch and commercialization of Lifileucel and clinical trial progress in other indications. Analyst estimates indicate significant revenue growth in the coming years.
Recent Initiatives: FDA approval and commercial launch of Lifileucel, expansion of clinical trials to other solid tumors, and investment in manufacturing capacity.
Summary
Iovance Biotherapeutics is strategically positioned as a pioneer in the TIL therapy market. The recent FDA approval and commercial launch of Lifileucel present a significant opportunity for revenue growth. However, the company faces challenges related to manufacturing complexity and competition from larger pharmaceutical companies. Successful expansion of Lifileucel to other indications and continued investment in research and development will be critical for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Iovance Biotherapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
- FDA.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Iovance Biotherapeutics Inc
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2010-10-15 | Interim CEO, President, General Counsel, Corporate Secretary & Director Dr. Frederick G. Vogt Esq., J.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 838 | Website https://www.iovance.com |
Full time employees 838 | Website https://www.iovance.com | ||
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.